Eam Investors, LLC Affimed N.V. Transaction History

Eam Investors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $1.89 Million - $2.56 Million	-341,209 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$7.78 - $11.4 $1.18 Million - $1.73 Million	-151,814 Reduced 30.79%	341,209 $2.9 Million
Q1 2021 May 11, 2021	BUY	$5.12 - $8.48 $1.21 Million - $2.01 Million	237,075 Added 92.63%	493,023 $3.9 Million
Q4 2020 Feb 11, 2021	BUY	$3.16 - $7.03 $808,795 - $1.8 Million	255,948 New	255,948 $1.49 Million
Q2 2019 Aug 14, 2019	SELL	$2.6 - $4.21 $349,871 - $566,522	-134,566 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$3.05 - $4.34 $41,110 - $58,498	-13,479 Reduced 9.1%	134,566 $565,000
Q4 2018 Feb 13, 2019	SELL	$2.82 - $4.67 $7,949 - $13,164	-2,819 Reduced 1.87%	148,045 $460,000
Q3 2018 Nov 08, 2018	BUY	$1.45 - $6.15 $218,752 - $927,813	150,864 New	150,864 $656,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.